Pharmaceuticals
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Taiwan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responden...
2023-11-07 08:15
1574
Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published
JINAN, China, Nov. 6, 2023 /PRNewswire/ -- Recently, the results of the Phase I study for iparomlimab (R&D code: QL1604), developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journalFrontiers in Immunology (2022 Impact Factor: 7.3). The title of the paper is "A first-i...
2023-11-06 18:54
2106
'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum
* 1 in 2 Diabetics and 1 in 10 Pre-diabetics estimated to suffer from PN * Vitamin B Deficiency affects quality of life of ~ 19% of all Diabetics * Unveil NEW NENOIN Study results on how B Vitamins improve sensory symptoms, motor function and motor strength in PN JAKARTA, Indonesia, Nov. 6, 2...
2023-11-06 17:07
2284
Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy subjects ha...
2023-11-06 12:20
2612
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-11-06 08:00
3884
Verismo Therapeutics Announces Upcoming Presentation at SITC 2023
PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology today announced that it will be presenting at the upcoming Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023), to be held in San Diego and ...
2023-11-03 21:00
3076
Lion TCR clinched the prestigious T-Up Excellence Awards in Singapore
SINGAPORE, Nov. 2, 2023 /PRNewswire/ -- At the annual Singapore Week of Innovation and Technology (SWITCH) 2023, Lion TCR, a clinical-stage mRNA-based T cell immunotherapy company, is thrilled to announce a significant milestoneof clinching the T-Up Excellence Awards. This award, in recognitio...
2023-11-02 20:41
3401
European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC)
- BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC - The application is based on results from the PHAROS study,[1] which showed an objective response rate of 75% in treatment-naïve patients and 46% in previou...
2023-11-02 18:52
1178
Cambrex Announces Sale of Drug Product Business Unit
EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit toWilmington, Delaware based Noramco. Cambrex's Drug Product business provides product developme...
2023-11-02 18:00
2323
Xinhua Silk Road: 54th Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi
BEIJING, Nov. 2, 2023 /PRNewswire/ -- The 54th Zhangshu National Traditional
Chinese Materia Medica Trade Fair was held recently in Zhangshu, a county-level
city in eastChina's Jiangxi Province.
2023-11-02 14:21
2970
TraceLink MINT Wins 2023 Pharma Innovation Award: 100% End-to-End Supply Chain Digitalization is Now Within Reach
100% End-to-End Supply Chain Digitalization is Now Possible with Proven Network Orchestration Capability BOSTON, Nov. 2, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life...
2023-11-02 05:22
2321
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Clinical Dermatology Conference HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Nov. 1, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries,...
2023-11-01 22:07
3114
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainlandChina. CStone to retain the rights to nofazinlimab outside mainland China. * This partnership will combine the strengths of CStone a...
2023-11-01 18:10
4437
Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
LONDON, Nov. 1, 2023 /PRNewswire/ -- Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be ...
2023-11-01 09:05
1335
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2023-11-01 08:30
2085
BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ Ventures
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the deve...
2023-10-31 21:00
4256
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-31 20:30
1994
Select the Right Medical-Grade TPU：ICP DAS - BMP Launches a New TPU Series at COMPAMED & IPF Japan 2023
HSINCHU, Oct. 31, 2023 /PRNewswire/ -- ICP DAS – Biomedical Polymers, Asia's first medical-grade TPU (thermoplastic polyurethane) manufacturer and supplier, will be exhibiting at COMPAMED inGermany and IPF in Japan in November and December 2023. The company proudly presents its new Arothane™ ARP-...
2023-10-31 16:38
2997
Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore
SINGAPORE, Oct. 31, 2023 /PRNewswire/ -- Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held inSingapore. The ...
2023-10-31 15:42
2506
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. * This marks sugemalimab's third indication approved in China following Stage III and IV non-small cell lung cancer (NSCLC) and the ...
2023-10-31 10:16
3148
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 276 media titles]
2026-02-17 19:12
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Philips Evnia x SEGA: Elevating Immersion for YAKUZA KIWAMI 3 & DARK TIES | Unveiling the 27M2N6501L QD-OLED Monitor - Where Speed Meets Spectacle
[Picked up by 260 media titles]
2026-02-12 15:58
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
7697
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7135
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
6688
